Peer Review History
| Original SubmissionMarch 11, 2020 |
|---|
|
PONE-D-20-07014 Metabolic engineering considerations for the heterologous expression of xylose-catabolic pathways in Saccharomyces cerevisiae PLOS ONE Dear Kim, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Two of the three reviewer found partial merit in your paper. However, before it could be considered for acceptance in PLOS ONE, major revisions are needed. Plese follow the reviewers' suggestion and reply to all the comments from the three reviewers, with whom I essentially agree. We would appreciate receiving your revised manuscript by Jun 21 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Enrico Baruffini, Ph.D. Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: N/A Reviewer #2: Yes Reviewer #3: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: In this study the authors compare two well-established strategies of generating a xylose fermenting strain of S. cerevisiae – introduction of the oxidoreductase pathway or the xylose isomerase pathway. Establishing a xylose fermenting yeast strain is important because xylose ifs the major non-glucose component of much plant biomass, and it would be useful to be able to turn it into ethanol along with the glucose in a single fermentation reaction. Various approaches to optimize these pathways have been investigated in the past, this study builds on these observations, and compares them in the two essentially isogenic strains engineered to have the two pathways. The main conclusions are the oxidoreductase pathway responds to changes in Pho13 and Tal1 and to the adaptive evolution protocol implemented, while the isomerase strain responded to increasing the isomerase levels, and that the direct comparison suggests the oxidoreductase pathway may provide the more attractive strategy for generating the xylose fermenting S. cerevisiae strain. This manuscript seems to fall between a research paper and a review. The majority of the work is essentially repeating a set of previously identified strain modifications in a pair of strains identical except for the added xylose metabolic enzymes; fundamentally consolidating information without providing anything new. The stated goal was to establish the framework for improved production using the isomerase modified strain, but this was not successful – the improvements were limited to increasing levels of the heterologous enzyme. Thus the paper really fails in its ultimate aim, and provides little new in this process. Providing a clear picture of why modifications that work in one framework fail in the other would be useful, but the current format is of very limited value. Reviewer #2: The authors of the manuscript under review have constructed and compared yeast strains expressing two different pathways for xylose utilization. Some findings reported in the manuscript differ from those reported in earlier studies, and merit a thorough discussion. Lines 83-86 and 299-303: Prior studies have shown that deleting the PHO13 gene increases xylose uptake and ethanol production in xylose isomerase-expressing strains (for example, Biotechnol Biofuels 2014 7:122; AMB Express 2016 6:4). Lines 198-200: Details about the integration site should be provided. Lines 201 ff: Why did XYL123 and XI-XYL3 exhibit different xylose fermentation patterns? This should be discussed. Lines 233-235: Transcriptional profiling of a pho13 mutant has been shown to upregulate the PP pathway irrespective of the sugar substrate used (Appl Environ Microbiol 2015 81:1601-1609; see Table 4 for TAL1 overexpression). As the results obtained by the authors differ from these findings, this merits a thorough discussion. Lines 236-240 and 260-267: The authors should discuss why deletion of PHO13 has different effects in strains expressing different xylose assimilation pathways. This is especially important because the results obtained by the authors differ from those reported by other researchers (for example, Biotechnol Biofuels 2014 7:122; AMB Express 2016 6:4). The probable reason for this difference should be discussed. Lines 288-291 and 321-322: What is the desired expression level of xylA? An earlier report has demonstrated that two copies of a mutant xylose isomerase are sufficient to achieve high xylose consumption and ethanol production rates (Biotechnol Biofuels 2014 7:122). Lines 323-325: Do the authors expect that different results would be obtained when genes involved in xylose assimilation from other yeast species are overexpressed? Why would that be the case? Lines 325-328: The interplay of cell density and dissolved oxygen is crucial in determining strain performance. The authors should discuss why the XI-expressing strain performs better under anaerobic conditions. Lines 341-344: The beneficial effect of PHO13 in XI-expressing strains has been shown to be independent of strain background (Appl Environ Microbiol 2015 81:1601-1609). Expression of xylA from different sources has not been found to affect transcription profiles in yeast (Appl Biochem Biotechnol 2019 189:1007-1019). Lines 350-352: This is a highly subjective conclusion. The XI pathway is cofactor-independent, and several studies have used the XI pathway to construct efficient xylose-fermmenting strains (for example, BMC Biotechnol 2013 13:110; PLoS Genet 2015 11:e1005010; Front Microbiol 2015 6:1165; Bioresour Bioprocess 2016 3:51). A note on methods employed: Sufficient details should be provided in the manuscript to enable readers to understand procedures employed without referring to earlier published work. For example, how was cDNA synthesized (line 135)? Which column was used for HPLC analysis (line 155)? A note on genetic nomenclature: Gene deletions in yeast should be designated by use of lower case letters in italics alone. Reviewer #3: The manuscript by Jeong et al. compares the use of the oxidoreductase and the isomerase pathways for xylose utilization by S. cerevisiae and concludes that the oxidoreductase pathway provides simpler metabolic engineering strategies. This conclusion is oversimplified and is not supported by the results. This work has sound and interesting experimental results but its presentation and discussion present several flaws and misconceptions. Authors used metabolic engineering strategies previously reported to be successful in XR/XDH engineered strains and confirm its validity for XR/XDH and verify that those are not successful in XI. This should not be surprising as these pathways will affect cell metabolism in a different way. In my opinion, instead of comparing the two pathways directly and choose one that provides simper metabolic engineering strategies, authors should discuss the results obtained for the two pathways and relate those with cell metabolism. One important reference related to this topic is Cunha et al 2019 Biotechnol Biofuels 12(20) that should be introduced in the introduction section and discussed. Some guidelines are given below on how to redirect results discussion. 1) The integration site chosen for both pathways is the ALD6 gene. Are there any evidences that the deletion of this gene affects equally both pathways? As ALD6 codes for a cytosolic aldehyde dehydrogenase that utilizes NADP+ as the preferred coenzyme, besides increasing the flux to ethanol which will consume NADH and produce NAD+, I doubt. As the authors refer in the introduction the XI pathway is cofactor-independent while XR/XDH is cofactor-dependent, presenting a shortage of NAD+. Thus, the comparison might be bias from the very beginning. The decision of deleting ALD6 in the host of the two pathways should be better explained or authors may consider to not delete ALD6. 2) The two strains show completely different physiology on xylose containing media with the strain harbouring the XI pathway presenting xylitol accumulation. Authors attribute the significant accumulation of xylitol by the XI-XYL3 strain to endogeneous enzymes like the non-specific aldose reductase code by GRE3. This has to be better explained as both hosts have the same endogeneous enzymes but only one presents accumulation of xylitol. This could also be related with the point I raised before. 3) On the discussion section, authors state that there is no clear and simple approach to design efficient S. cerevisiae strain with XI pathway. This sentence and the following one, makes no sense as there are several works in literature that use this pathway (XI) together with other modifications. For instance, Cunha et al. 2019 Biotechnol Biofuels 12(20). 4) The authors refer that the copy number increase in xylose isomerase gene is the most critical for XI pathway. What about the enzyme itself? The enzyme efficiency? 5) On page 16, lines 326-327, authors state that under anaerobic conditions with high initial cell density were the XI-XYL3 strain produces ethanol at higher yield than strains with XR/XDH pathway. These comparison makes no sense. Authors compare the XI-XYL3 strain with 25 gDCW/L inoculum with the XYL123 strain with 0.5 gDCW/L. 6) Page 16, lines 329-332: Makes no sense. The XI pathway needs other additional modifications not necessarily the same that function with XR/XDH. Authors should also look into papers that have successful strategies with XI pathway. 7) Pg. 16, line 336, SOR1 deletion has significantly increased growth rate; these results should be better discussed. Again, from the results one may consider that the deletion of ALD6 could be detrimental for XI expression. 8) On M&M, in the section of HPLC analysis, the column and conditions should be given here 9) Pg. 12, Line 243, high? Replace by Concentrations of xylose higher than 10 g/L… 10) Pg. 14, line289, what are these desired expression levels? Some achieved in other studies referred in Table 3 using this xylA gene? 11) Pg. 16 line 345, it is not true as an initial deletion of ALD6 has been made 12) Pg. 17 line 351-352, conclusion not supported by data 13) Table 2, no results on acetate quantification are given, if it was not detected, this information is missing. 14) Table 1, XYL123 is not presented in the table ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No Reviewer #3: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
Metabolic engineering considerations for the heterologous expression of xylose-catabolic pathways in Saccharomyces cerevisiae PONE-D-20-07014R1 Dear Dr. Kim, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Enrico Baruffini, Ph.D. Academic Editor PLOS ONE Additional Editor Comments (optional): After the first revision, the reviewers found merit in your work, which can now be accepted by PLOS ONE. Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #2: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: N/A Reviewer #2: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: (No Response) Reviewer #2: The authors have adequately addressed the comments raised on the earlier manuscript, and have revised the manuscript accordingly. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No |
| Formally Accepted |
|
PONE-D-20-07014R1 Metabolic engineering considerations for the heterologous expression of xylose-catabolic pathways in Saccharomyces cerevisiae Dear Dr. Kim: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Enrico Baruffini Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .